Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human AKR1C4 Protein, GST-tagged

Cat.No. : AKR1C4-414H
Product Overview : Human AKR1C4 full-length ORF ( AAH20744, 1 a.a. - 323 a.a.) recombinant protein with GST-tag at N-terminal.
  • Specification
  • Gene Information
  • Related Products
Description : This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the bioreduction of chlordecone, a toxic organochlorine pesticide, to chlordecone alcohol in liver. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. [provided by RefSeq, Jul 2008]
Source : Wheat Germ
Species : Human
Tag : GST
Molecular Mass : 61.27 kDa
AA Sequence : MDPKYQRVELNDGHFMPVLGFGTYA PPEVPRNRAVEVTKLAIEAGFRHID SAYLYNNEEQVGLAIRSKIADGSVK REDIFYTSKLWCTFFQPQMVQPALE SSLKKLQLDYVDLYLLHFPMALKPG ETPLPKDENGKVIFDTVDLSATWEV MEKCKDAGLAKSIGVSNFNYRQLEM ILNKPGLKYKPVCNQVECHPYLNQS KLLDFCKSKDIVLVAHSALGTQRHK LWVDPNSPVLLEDPVLCALAKKHKR TPALIALRYQLQRGVVVLAKSYNEQ RIRENIQVFEFQLTSEDMKVLDGLN RNYRYVVMDFLMDHPDYPFSDEY
Applications : Enzyme-linked Immunoabsorbent Assay; Western Blot (Recombinant protein); Antibody Production; Protein Array
Notes : Best use within three months from the date of receipt of this protein.
Storage : Store at -80 centigrade. Aliquot to avoid repeated freezing and thawing.
Storage Buffer : 50 mM Tris-HCI, 10 mM reduced Glutathione, pH=8.0 in the elution buffer.
Gene Name : AKR1C4 aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4) [ Homo sapiens ]
Official Symbol : AKR1C4
Synonyms : AKR1C4; aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4); CHDR; aldo-keto reductase family 1 member C4; 3 alpha HSD; C11; CDR; DD4; HAKRA; MGC22581; 3-alpha-HSD1; dihydrodiol dehydrogenase isozyme DD4; type I 3-alpha-hydroxysteroid dehydrogenase; DD-4; 3-alpha-HSD;
Gene ID : 1109
mRNA Refseq : NM_001818
Protein Refseq : NP_001809
MIM : 600451
UniProt ID : P17516

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (11)

Ask a question
Are there any ongoing clinical trials targeting AKR1C4? 12/04/2021

Currently, there are limited ongoing clinical trials specifically targeting AKR1C4. However, there are studies investigating the role of AKR1C4 in cancer and drug metabolism, which may indirectly contribute to the development of targeted therapies. Ongoing research may uncover additional therapeutic opportunities for AKR1C4 and lead to the initiation of clinical trials in the future.

Are there any known drug interactions or adverse effects associated with AKR1C4 inhibitors? 11/13/2021

While AKR1C4 inhibitors have shown potential therapeutic benefits, they may also have interactions with other medications. This is particularly relevant in the context of drug metabolism, as AKR1C4 plays a role in the clearance of certain drugs. Therefore, the use of AKR1C4 inhibitors in combination with other medications should be carefully evaluated to avoid potential adverse effects or altered drug concentrations in the body. Additionally, the specific side effects or toxicity profiles of AKR1C4 inhibitors may vary depending on the compound used and further studies are needed to fully understand their safety profile.

What are the tissue distribution and cellular localization of AKR1C4? 10/21/2021

AKR1C4 is expressed in various tissues, including the liver, kidney, prostate, breast, and lung. It is found in both the cytoplasm and nucleus of cells. The specific cellular localization of AKR1C4 can vary depending on the cell type and its specific functions within that cell.

Can targeting AKR1C4 have therapeutic implications? 02/02/2021

Targeting AKR1C4 has emerged as a potential therapeutic strategy in certain conditions. Inhibition of AKR1C4 activity may be explored for the treatment of hormone-dependent cancers, such as prostate cancer. Additionally, modulating AKR1C4 activity may have implications for conditions involving inflammation and immune responses. However, further research is needed to fully understand its therapeutic potential.

Is AKR1C4 used as a biomarker for any diseases or conditions? 02/19/2020

Currently, AKR1C4 is not widely used as a biomarker for specific diseases or conditions. However, its expression and activity levels have been investigated in various studies as a potential biomarker for certain cancers and inflammatory disorders. Further research is needed to determine its clinical utility as a biomarker.

Is AKR1C4 involved in any genetic disorders? 01/24/2020

Yes, mutations in the AKR1C4 gene have been associated with a rare genetic disorder called congenital adrenal hyperplasia (CAH). CAH is characterized by impaired steroid hormone production and can manifest as ambiguous genitalia in affected individuals.

What are the potential therapeutic applications of targeting AKR1C4? 09/25/2018

Targeting AKR1C4 has shown potential therapeutic applications in various fields. In cancer treatment, inhibiting AKR1C4 can potentially enhance the efficacy of chemotherapy drugs by preventing their inactivation. AKR1C4 inhibitors may also be useful in the treatment of hormone-related cancers such as breast and prostate cancers, as the enzyme is involved in the metabolism of sex hormones. Additionally, targeting AKR1C4 may be explored in the development of therapies for endometriosis, neuroinflammatory conditions, and hypertension, based on its involvement in these diseases.

Are there any known genetic variations or polymorphisms in AKR1C4? 06/24/2017

Yes, several genetic variations and polymorphisms in AKR1C4 have been identified. Some of these variations have been associated with altered enzyme activity and drug metabolism. Certain polymorphisms may also impact the susceptibility to certain diseases or influence the response to specific medications. However, more research is needed to fully understand the functional impact of these genetic variations.

Are there any specific inhibitors or activators of AKR1C4? 02/19/2017

Several compounds have been identified as inhibitors or activators of AKR1C4. For example, various nonsteroidal anti-inflammatory drugs (NSAIDs) such as flufenamic acid and its analogs have been shown to inhibit AKR1C4 activity. On the other hand, some compounds like resveratrol and certain phytoestrogens can activate AKR1C4. However, the specificity and selectivity of these compounds towards AKR1C4 and their potential therapeutic applications require further investigation.

Does AKR1C4 have any physiological or pathophysiological roles outside of cancer and drug metabolism? 05/27/2016

Yes, AKR1C4 is involved in various physiological and pathophysiological processes outside of cancer and drug metabolism. It plays a role in the regulation of blood pressure by metabolizing important vasoactive compounds called prostaglandins. AKR1C4 is also implicated in endometriosis, a gynecological disorder characterized by the growth of endometrial tissue outside the uterus. Additionally, recent studies have suggested a potential role for AKR1C4 in neuroinflammation and neurological disorders.

How is AKR1C4 related to drug metabolism? 03/22/2016

AKR1C4 is involved in the metabolism of various drugs and xenobiotics. It can catalyze the reduction or oxidation of certain compounds, influencing their pharmacological properties and elimination from the body. AKR1C4 plays a role in the metabolism of nonsteroidal anti-inflammatory drugs (NSAIDs), anti-inflammatory corticosteroids, and some antipsychotic medications.

Customer Reviews (4)

Write a review
Reviews
12/06/2022

    The AKR1C4 protein is known for its exceptional quality, making it a highly suitable choice for meeting diverse experimental needs.

    02/05/2021

      One notable advantage of the AKR1C4 protein is the excellent technical support provided by its manufacturer.

      10/02/2020

        Renowned for its reliability and consistency, this protein offers researchers the confidence to achieve accurate and reproducible results in their studies.

        08/06/2016

          Its versatility and reliability make it an indispensable asset for scientists seeking to explore the complexities of various biological systems.

          Ask a Question for All AKR1C4 Products

          Required fields are marked with *

          My Review for All AKR1C4 Products

          Required fields are marked with *

          0

          Inquiry Basket

          cartIcon
          logo

          FOLLOW US

          Terms and Conditions        Privacy Policy

          Copyright © 2024 Creative BioMart. All Rights Reserved.

          Contact Us

          • /

          Stay Updated on the Latest Bioscience Trends